Other Events ·
On August 19, 2026, Korro Bio announced the submission of an application to the Australian Alfred Health Human Ethics…
KRROKorro Bio, Inc.
On August 19, 2026, Korro Bio announced the submission of an application to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121. This GalNAc-conjugated RNA editing oligonucleotide is in development for the potential treatment of hyperammonemia in patients with Urea Cycle Disorders (UCDs). The trial aims to determine safety, tolerability, pharmacokinetics, and efficacy in healthy volunteers and participants with UCDs under ClinicalTrials.gov identifier NCT 07773246. Korro Bio operates as a biopharmaceutical company focused on developing genetic medicines.